KeyBanc Cuts Adeptus Health's Price Target From $59 To $31


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


After reporting far worse-than-expected Q3 results and announcing that the company will be exploring various financial alternatives through Goldman Sachs, shares of Adeptus Health Inc (NYSE: ADPT) were trading more than 60 percent lower.

While firms Bank of America and Jefferies have downgraded the stock, KeyBanc Capital Markets analyst Jason Gurda maintained an Overweight rating, but drastically lowered his price target from $59 to $31.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Gurda cited the “extremely disappointing” performance and stated the near-term opportunity on shares of Adeptus is “a fraction of what it appeared to be earlier in the year.”

In contrast, the analyst stated the Q3 results understate the near-term opportunity and the value Adeptus facilities would have to a potential acquirer.

Additionally, Gurda said that the volume and accounts receivable issues Adeptus is experiencing are “ultimately addressable” through its hospital outpatient department (HOPD) partnership strategy.

The stock traded recently at $9.06, down 66.3 percent.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: Analyst ColorPrice TargetAnalyst RatingsJason GurdaKeyBanc